Meningitis - Drug Pipeline Landscape, 2023

Meningitis - Drug Pipeline Landscape, 2023

Meningitis is an inflammation of the fluid and membranes (meninges) surrounding your brain and spinal cord. Meningitis can be caused by a bacterial, fungal or viral infection.

Viral infections are the most common cause of meningitis, followed by bacterial infections and, rarely, fungal and parasitic infections. Less common causes of meningitis include autoimmune disorder, cancer medicines.

Meningitis symptoms include confusion, fever, headache numbness, sensitivity to light, stiff neck, upset stomach or vomiting, seizures, sleepiness, lack of appetite, lack of thirst, skin rash, syphilis and tuberculosis.

Diagnosing meningitis begins with a health history and physical exam. During the physical exam, doctor will look for, fever and skin issues. Other tests may also be ordered to diagnose meningitis including blood cultures, X-rays, CT scan, MRI Scan and Spinal tap.

Bacterial meningitis is treated with intravenous antibiotics and sometimes corticosteroids right away. The antibiotic or combination of antibiotics depends on the type of bacteria causing the infection. Viral meningitis treatment includes bed rest, plenty of fluids, over-the-counter pain medications. Antifungal medications treat fungal meningitis, and a combination of specific antibiotics can treat tuberculous meningitis. Noninfectious meningitis due to allergic reaction or autoimmune disease may be treated with corticosteroids.

Some companies that are active in the development of meningitis drugs include Pfizer, GlaxoSmithKline, and Sanofi.

There are many clinical trials ongoing in meningitis drug development. Some of the most promising and active areas of research include new vaccines, new drug therapies, and new diagnostic tools.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Meningitis treatment such as GSK3536829A, GSK3536819A, GSK4023393A, SP0230 and others. Key players involved in the development of therapies to treat Meningitis are GlaxoSmithKline, Matinas BioPharma Nanotechnologies, Inc, Pfizer, Sanofi, Walvax Biotechnology Co Ltd and others. Six drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I and preclinical stages of development.

Report Highlights

Global Insight Service's, Meningitis - Drug Pipeline Landscape, 2023 report provides an overview of the Meningitis pipeline drugs. This report covers detailed insights on Meningitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Meningitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.